Two Sigma Advisers LP Makes New $722,000 Investment in Sangamo Therapeutics, Inc. (NASDAQ:SGMO)

Two Sigma Advisers LP purchased a new stake in Sangamo Therapeutics, Inc. (NASDAQ:SGMO - Free Report) in the 4th quarter, according to its most recent disclosure with the SEC. The fund purchased 707,555 shares of the biopharmaceutical company's stock, valued at approximately $722,000. Two Sigma Advisers LP owned 0.34% of Sangamo Therapeutics as of its most recent filing with the SEC.

Several other hedge funds and other institutional investors have also modified their holdings of SGMO. E Fund Management Co. Ltd. acquired a new position in shares of Sangamo Therapeutics in the 4th quarter valued at about $25,000. JPMorgan Chase & Co. boosted its holdings in shares of Sangamo Therapeutics by 679.5% in the 4th quarter. JPMorgan Chase & Co. now owns 25,000 shares of the biopharmaceutical company's stock valued at $26,000 after buying an additional 21,793 shares during the period. PNC Financial Services Group Inc. boosted its holdings in shares of Sangamo Therapeutics by 2,319.1% in the 4th quarter. PNC Financial Services Group Inc. now owns 26,078 shares of the biopharmaceutical company's stock valued at $27,000 after buying an additional 25,000 shares during the period. SBI Securities Co. Ltd. acquired a new position in shares of Sangamo Therapeutics in the 4th quarter valued at about $28,000. Finally, Captrust Financial Advisors acquired a new position in shares of Sangamo Therapeutics in the 4th quarter valued at about $30,000. 56.93% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several research analysts have recently commented on the stock. HC Wainwright reaffirmed a "buy" rating and issued a $10.00 price target on shares of Sangamo Therapeutics in a report on Monday, April 7th. Royal Bank of Canada reissued a "sector perform" rating and set a $2.00 target price on shares of Sangamo Therapeutics in a research note on Tuesday, March 18th. Wall Street Zen lowered shares of Sangamo Therapeutics from a "hold" rating to a "sell" rating in a research note on Friday, May 30th. Finally, Barclays reduced their target price on shares of Sangamo Therapeutics from $9.00 to $5.00 and set an "overweight" rating for the company in a research note on Wednesday, May 14th. One research analyst has rated the stock with a sell rating, two have issued a hold rating and four have issued a buy rating to the company's stock. Based on data from MarketBeat.com, the company currently has an average rating of "Hold" and a consensus target price of $4.50.

Sangamo Therapeutics Trading Down 1.6%

Sangamo Therapeutics stock traded down $0.01 during midday trading on Wednesday, reaching $0.49. 3,203,320 shares of the stock traded hands, compared to its average volume of 6,083,129. The firm has a fifty day moving average price of $0.63 and a two-hundred day moving average price of $1.16. The firm has a market cap of $114.72 million, a price-to-earnings ratio of -0.66 and a beta of 1.46. Sangamo Therapeutics, Inc. has a fifty-two week low of $0.30 and a fifty-two week high of $3.18.

Sangamo Therapeutics (NASDAQ:SGMO - Get Free Report) last released its quarterly earnings results on Monday, May 12th. The biopharmaceutical company reported ($0.14) EPS for the quarter, missing analysts' consensus estimates of ($0.11) by ($0.03). Sangamo Therapeutics had a negative return on equity of 264.16% and a negative net margin of 257.87%. The company had revenue of $6.44 million for the quarter, compared to the consensus estimate of $7.90 million. Analysts anticipate that Sangamo Therapeutics, Inc. will post -0.46 earnings per share for the current year.

Sangamo Therapeutics Company Profile

Sangamo Therapeutics, Inc, a clinical-stage genomic medicine company, focuses on translating science into medicines that transform the lives of patients and families afflicted with serious diseases in the United States. The company's clinical-stage product candidates are ST-920, a gene therapy product candidate, which is in Phase 1/2 clinical study for the treatment of Fabry disease; TX200, a chimeric antigen receptor engineered regulatory T cell (CAR-Treg) therapy product candidate that is in Phase 1/2 clinical study for the prevention of immune-mediated rejection in HLA-A2 mismatched kidney transplantation; SB-525, a gene therapy product candidate, which is in Phase 3 clinical trial for the treatment of moderately severe to severe hemophilia A; BIVV003, a zinc finger nuclease gene-edited cell therapy product candidate that is in Phase 1/2 PRECIZN-1 clinical study for the treatment of sickle cell disease.